Overview
- Official Redecan and SEOM data show age‑adjusted incidence rising since 2004, reaching 21.7 per 100,000 in men and 16.4 in women in 2025.
- Spain recorded 7,973 deaths in 2022, placing pancreatic cancer among the deadliest malignancies, with five‑year survival of about 10–12% and slightly higher rates in women.
- Clinicians report that roughly half of patients present with metastases, about 30% have locally advanced disease, and only around 20% are candidates for surgery at diagnosis.
- Warning signs include jaundice, unexplained weight loss, persistent abdominal or back pain, dark urine, pale stools, and recent‑onset diabetes, triggering rapid workups using high‑specificity imaging and endoscopic ultrasound with biopsy in some centers.
- Care remains multidisciplinary: surgery for the resectable minority and systemic chemotherapy for advanced disease, with PARP inhibitors for BRCA‑mutated patients and KRAS‑targeted drugs and immunotherapy combinations being tested in trials; tobacco, obesity, sedentary behavior, unhealthy diet, alcohol, and hereditary syndromes drive risk.